ASH 2025 preview – Kelonia gets a late-breaking coup
An in vivo Car-T produced a 100% response rate – in three patients.
Argenx’s efforts to Advance fall flat
Failure of a subcutaneous formulation of Vyvgart raises questions about the drug’s future in primary immune thrombocytopenia and beyond.
